CO6280469A2 - Complejo de acido nucleico y composicion de suministro de acidos nucleicos - Google Patents

Complejo de acido nucleico y composicion de suministro de acidos nucleicos

Info

Publication number
CO6280469A2
CO6280469A2 CO10068754A CO10068754A CO6280469A2 CO 6280469 A2 CO6280469 A2 CO 6280469A2 CO 10068754 A CO10068754 A CO 10068754A CO 10068754 A CO10068754 A CO 10068754A CO 6280469 A2 CO6280469 A2 CO 6280469A2
Authority
CO
Colombia
Prior art keywords
nucleic acid
cell
complex
acid complex
supply composition
Prior art date
Application number
CO10068754A
Other languages
English (en)
Inventor
Hirofumi Takeuchi
Yuichi Tozuka
Yasuyuki Hira
Hidekazu Toyobuku
Original Assignee
Otsuka Pharma Co Ltd
Hirofumi Takeuchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Hirofumi Takeuchi filed Critical Otsuka Pharma Co Ltd
Publication of CO6280469A2 publication Critical patent/CO6280469A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

La presente invención proporciona un complejo de ácido nucleico con baja toxicidad y alta seguridad que puede mantener persistentemente un ácido nucleico, tal cómo siARN o similares en una célula y una composición de suministro de ácido nucleico que puede suministrar eficientemente el complejo de ácido nucleico en una célula. Se puede obtener un complejo de ácido nucleico con baja toxicidad y alta seguridad que puede mantener persistentemente un ácido nucleico en una célula al formar un complejo utilizando un ácido nucleico para ser introducido en una célula, y una dextrina cíclica altamente ramificada. Más aún, cuando un portador que comprende (A) una diacilfosfatidilcolina, (B) colesterol y/o un derivado del mismo, y (C) una amina primaria alifática se utiliza como un portador de suministro de ácido nucleico para introducir el complejo de ácido nucleico en una célula, se puede mejorar adicionalmente la seguridad, la eficiencia de suministro intracelular, y la persistencia del ácido nucleico en la célula.
CO10068754A 2007-11-08 2010-06-08 Complejo de acido nucleico y composicion de suministro de acidos nucleicos CO6280469A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007291317 2007-11-08

Publications (1)

Publication Number Publication Date
CO6280469A2 true CO6280469A2 (es) 2011-05-20

Family

ID=40303461

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10068754A CO6280469A2 (es) 2007-11-08 2010-06-08 Complejo de acido nucleico y composicion de suministro de acidos nucleicos

Country Status (28)

Country Link
US (1) US8338584B2 (es)
EP (1) EP2217208B1 (es)
JP (1) JP5340282B2 (es)
KR (1) KR101567108B1 (es)
CN (1) CN101854918B (es)
AR (1) AR069224A1 (es)
AT (1) ATE522201T1 (es)
AU (1) AU2008325504B2 (es)
BR (1) BRPI0819187A2 (es)
CA (1) CA2704236C (es)
CO (1) CO6280469A2 (es)
CY (1) CY1112029T1 (es)
DK (1) DK2217208T3 (es)
ES (1) ES2369869T3 (es)
HK (1) HK1142278A1 (es)
HR (1) HRP20110698T1 (es)
IL (1) IL205237A0 (es)
MX (1) MX2010005094A (es)
MY (1) MY149917A (es)
NZ (1) NZ584841A (es)
PL (1) PL2217208T3 (es)
PT (1) PT2217208E (es)
RU (1) RU2465009C2 (es)
SI (1) SI2217208T1 (es)
TW (1) TWI426922B (es)
UA (1) UA97559C2 (es)
WO (1) WO2009061003A2 (es)
ZA (1) ZA201002845B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
AR083445A1 (es) 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
RU2582235C2 (ru) 2010-12-29 2016-04-20 Ф.Хоффманн-Ля Рош Аг Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
SG11201403816YA (en) * 2012-03-15 2014-08-28 Acraf Glycogen-based cationic polymers
US20200363389A1 (en) * 2017-12-27 2020-11-19 Konica Minolta, Inc. Method for Assessing Medicine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01238537A (ja) * 1988-03-18 1989-09-22 Toyo Jozo Co Ltd 肝障害治療剤
JP3150266B2 (ja) * 1994-04-01 2001-03-26 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
JP3107358B2 (ja) 1994-09-13 2000-11-06 江崎グリコ株式会社 環状構造を有するグルカンおよびその製造方法
US6248566B1 (en) * 1994-09-13 2001-06-19 Ezaki Glico Co., Ltd. Glucan having cyclic structure and method for producing the same
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5827697A (en) 1995-03-31 1998-10-27 Ezaki Glico Co., Ltd. Process for preparing glucans having a cyclic structure
US20030092180A1 (en) 2001-08-27 2003-05-15 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
JPH11292795A (ja) 1998-04-02 1999-10-26 Yamanouchi Pharmaceut Co Ltd Ｈｉｖコファクター抑制剤
JP4854853B2 (ja) 1998-11-12 2012-01-18 ライフ テクノロジーズ コーポレーション トランスフェクション薬剤
US20030157030A1 (en) * 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
RU2289585C2 (ru) * 2002-02-04 2006-12-20 Корикса Корпорейшн Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа
US20040204420A1 (en) * 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
US20060228420A1 (en) * 2005-03-15 2006-10-12 Queen Mary & Westfield College Pharmaceutical compositions comprising microparticles for delivery into neurons

Also Published As

Publication number Publication date
JP5340282B2 (ja) 2013-11-13
MY149917A (en) 2013-10-31
RU2465009C2 (ru) 2012-10-27
CN101854918B (zh) 2012-11-28
AU2008325504A1 (en) 2009-05-14
CA2704236A1 (en) 2009-05-14
TWI426922B (zh) 2014-02-21
WO2009061003A2 (en) 2009-05-14
RU2010123168A (ru) 2011-12-20
SI2217208T1 (sl) 2011-11-30
CY1112029T1 (el) 2015-11-04
AR069224A1 (es) 2010-01-06
PT2217208E (pt) 2011-11-08
EP2217208B1 (en) 2011-08-31
MX2010005094A (es) 2010-05-27
EP2217208A2 (en) 2010-08-18
ZA201002845B (en) 2011-07-27
US20100305190A1 (en) 2010-12-02
KR101567108B1 (ko) 2015-11-06
NZ584841A (en) 2011-12-22
HK1142278A1 (en) 2010-12-03
HRP20110698T1 (hr) 2011-10-31
KR20100092007A (ko) 2010-08-19
IL205237A0 (en) 2010-11-30
WO2009061003A3 (en) 2010-05-27
DK2217208T3 (da) 2011-10-10
ATE522201T1 (de) 2011-09-15
AU2008325504B2 (en) 2013-03-07
JP2011504457A (ja) 2011-02-10
CN101854918A (zh) 2010-10-06
TW200927175A (en) 2009-07-01
ES2369869T3 (es) 2011-12-07
UA97559C2 (uk) 2012-02-27
CA2704236C (en) 2015-09-15
BRPI0819187A2 (pt) 2015-05-05
US8338584B2 (en) 2012-12-25
PL2217208T3 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
DOP2022000152A (es) Vacunas de arn contra el coronavirus
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
CO6280469A2 (es) Complejo de acido nucleico y composicion de suministro de acidos nucleicos
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
AR075577A1 (es) Soluciones amino alcoholicas fertilizantes de triamida n- (n-butil) tiofosforica (nbpt) y urea para usar dichas soluciones como inhibidores de ureasa
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
UY32454A (es) SOLUCIONES AMORTIGUADAS DE AMINOALCOHOL DE N-(n-butil) TRIAMIDA TIOFOSFORICA (NBPT) Y FERTILIZANTES DE UREA QUE UTILIZAN DICHAS SOLUCIONES COMO INHIBIDORES DE LA UREASA
PE20120115A1 (es) Composiciones y metodos para inhibir la expresion de genes del factor vii
AR090869A1 (es) COMPOSICIONES DE ARNi DE SERPINC1 Y SUS METODOS DE USO
BR112013000391B8 (pt) Composição de emulsão catiônica de óleo em água e seu uso
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
NZ584048A (en) Lipopeptides for delivery of nucleic acids
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
AR084978A1 (es) Metodo y composicion para suministrar ingrediente activo al aire y su uso
AR057553A1 (es) Composicion portadora para el suministro de un acido nucleico
SV2011003943A (es) Procedimiento para la preparacion de depsipeptidos ciclicos, opticamente activos, con 24 atomos anulares, que contienen acido lactico y acido fenil lactico, usando cepas fungicas de la especie rosellinia y de otros xilariaceos
MY171201A (en) New carbamate glycolipid and use thereof
BRPI0814260B8 (pt) composição compreendendo um polímero de fita única, método compreendendo contatar uma célula com tal polímero e uso de tal polímero
AR065847A1 (es) Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso.
BR112014013906A2 (pt) ésteres de fosfato aromáticos como componentes de formulação agroquímica
CL2011000621A1 (es) Agente que contiene por lo menos un acido acilciclohexanodionacarboxilico y/o sus sales en combinacion con por lo menos un ester de acido acilciclohexanodionacarboxilico y su uso para mejorar el desarrollo de gramineas.

Legal Events

Date Code Title Description
FG Application granted